Ariel Dora Stern

Associate Professor

Harvard Business School

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ariel Dora Stern is an Associate Professor at Harvard Business School. She specializes in health technology policy, particularly focusing on digital health technologies, regulatory frameworks for medical devices, and the intersection of health data and outcomes. Her recent research examines topics such as the FDA's Biomarker Qualification Program and the uptake of digital health technologies in clinical trials. She is based in the United States.

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Susanne Boll

University of Oldenburg

GERMANY

View details

David Novillo-Ortiz

Unit Head, Data and Digital Health

DENMARK

View details

Mitchell Tang

Assistant Professor

Columbia University

UNITED STATES

View details

Divya Srivastava

Assistant Professor

St George’s, University of London

UNITED KINGDOM

View details

Christoffer Bjerre Haase

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ariel Dora Stern

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Participants in the FDA's Biomarker Qualification Program

Four Decades of Orphan Drugs and Priorities for the Future

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov

Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms

Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway

Building the Business Case for an Inclusive Approach to Digital Health Measurement With a Web App (Market Opportunity Calculator): Instrument Development Study

Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials

Effects of Remote Patient Monitoring Use on Care Outcomes Among Medicare Patients With Hypertension

Federated electronic health records for the European Health Data Space

Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping

Dynamic HTA for digital health solutions: opportunities and challenges for patient-centered evaluation

Regulatory considerations to keep pace with innovation in digital health products

Health app policy: international comparison of nine countries’ approaches

Regulatory, Legal, and Market Aspects of Smart Wearables for Cardiac Monitoring

Use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials

Remote Patient Monitoring — Overdue or Overused?

Ushering in safe, effective, secure, and ethical medicine in the digital era

Assessing the Food and Drug Administration’s Risk-Based Framework for Software Precertification With Top Health Apps in the United States: Quality Improvement Study

The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

Collaborators (5)

Susanne Boll

David Novillo-Ortiz

Mitchell Tang

Divya Srivastava

Christoffer Bjerre Haase

Make your next move.